
Biointron’s Q4 2024 annual antibody report aims to explore the events and trends of the biopharmaceutical industry in 2024 (October, November, December). This quarter, 6 novel antibody drugs have been approved by at least one regulatory agency around the world: three monoclonal antibodies, two bispecific antibodies, and one antibody-drug conjugate (ADC).
- Ongericimab (Junshida)
- Marstacimab (Hympavzi)
- Zanidatamab (Zilhera)
- Sacituzumab tirumotecan (佳泰莱)
- Zenocutuzumab (Bizengri)
- Cosibelimab (Unloxcyt)
Q4 2024 saw several large collaborations and acquisitions of up to USD$1.9 billion in value. Investment in antibody drug startups focused on novel antibody platforms changing glycans, structure, and the use of artificial intelligence.
Gain exclusive insights into current trends such as:
- 📣 6 novel antibody drugs approved for the first time in Q4
- 💸 Top 10 antibody drug deals, including collaborations, M&As, and funding rounds of up to US$1.9B
- 📈 A focus on novel platforms from startups with millions in seed funding
- 🤖 Exciting uses for AI in antibody discovery
- 💊 A list of antibody drugs in regulatory review to keep an eye out for in Q1 2025